Combination inhibition of MET and EGFR has shown increased PFS in patients with NSCLC with MET overexpression, and targeting HGF/MET may help overcome resistance to EGFR or VEGFR inhibitors [16]. This evidence concerns the gene MET and non-small cell lung carcinoma.